Idiosyncratic Liver Injury due to Rivaroxaban
Rivaroxaban is an oral direct factor Xa inhibitor that has been used for the primary and secondary prophylaxis of thromboembolic disorders. Once daily dosing makes it an attractive alternative when compared to other Novel Oral Anticoagulants (NOACS). Although, major and minor bleeding manifestatio...
Main Authors: | Aneesh Cherakulam Ratheendran, Mukund A Prabhu, KU Natarajan, Saritha Sekhar |
---|---|
Format: | Article |
Language: | English |
Published: |
JCDR Research and Publications Private Limited
2017-12-01
|
Series: | Journal of Clinical and Diagnostic Research |
Subjects: | |
Online Access: | https://jcdr.net/articles/PDF/11001/30329_F(P)_PF1(AD_GG)_PFA(MJ_GG).pdf |
Similar Items
-
Newer anticoagulants and their impact on interventional pain procedures
by: Babita Ghai, et al.
Published: (2017-01-01) -
Case report: Severe hepatopathy following rivaroxaban administration in a dog
by: Allison P. Mosichuk, et al.
Published: (2024-04-01) -
Rivaroxaban: Drug review
by: Abhishek Kumar Singh, et al.
Published: (2020-01-01) -
Rivaroxaban in acute venous thromboembolism: UK prescribing experience
by: Victoria Speed, et al.
Published: (2021-10-01) -
Conservatively managed saddle pulmonary embolism
by: Anna Meta Dyrvig Kristensen, et al.
Published: (2019-06-01)